Tuberculosis News and Research

Latest Tuberculosis News and Research

TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

In an effort to develop and deliver treatments for children with tuberculosis—answering a critical need in public health today—TB Alliance, a not-for-profit organization with the mission to develop better, faster-acting, and affordable drugs for TB, has entered into a collaboration with Svizera Europe, one of the leading global supply and distribution companies for TB treatments.

30 Oct 2013

Reduce tobacco consumption, reduce childhood asthma

A scientific study recently published on International Journal of Statistics in Medical Research states that tobacco consumption must be decreased by 15% in Spain, particularly at home, in order to reduce the number of childhood asthma cases.

30 Oct 2013

Study looks at the feasibility of Xpert test for TB in real-life clinical setting in southern Africa

The first randomised trial to measure the impact of the rapid Xpert MTB/RIF test for tuberculosis in a real-life clinical setting finds that it can be accurately performed by a non-specialist with minimal training, improves same-day diagnosis and time to starting treatment, and increases the number of people who start treatment after testing positive on day 1 by 50%, compared with conventional TB diagnostics.

30 Oct 2013

Researchers complete first phase of landmark study on fungal complications of TB

The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.

30 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Study finds persistent deficiency in new therapeutics for neglected diseases

In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development efforts. This continued 'fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.

25 Oct 2013

Researchers identify potential way to combat TB

Researchers have identified a potential way to manipulate the immune system to improve its ability to fight off tuberculosis.

24 Oct 2013

Tissue-engineered transplants safe and effective in the long term: Study

New results published in The Lancet today [Wednesday 23 October] reveal that five years after the first successful transplantation of a tissue-engineered airway (reported in The Lancet in 2008) the recipient continues to enjoy a good quality of life, and has not experienced any immunological complications or rejection of the implanted airway.

23 Oct 2013

APPG-GTB members express concern on the growing threat of multi-drug resistant TB

In a Lancet Comment discussing the WHO Global Tuberculosis report 2013 published today [Wednesday 23 October], members of the UK All-Party Parliamentary Group on Global Tuberculosis and lead author Professor Ali Zumla from University College London sound an alarm as the growing threat of multi-drug resistant TB to regional and global health security becomes more apparent.

23 Oct 2013

WHO report underlines need for quantum leap in TB care and control

Tuberculosis treatment has saved the lives of more than 22 million people, according to the WHO Global tuberculosis report 2013 published today. The report also reveals that the number of people ill with tuberculosis fell in 2012 to 8.6 million, with global TB deaths also decreasing to 1.3 million.

23 Oct 2013

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

The National Institute on Drug Abuse has awarded UCLA a $7 million grant to investigate the links between substance abuse and HIV among Latino and African-American men who have sex with men.

22 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, awarding Anacor $100 million in damages as well as all costs of the arbitration and reasonable attorney's fees.

18 Oct 2013

Psychotic symptoms alone denote medical health risk

People with symptoms of psychosis have an increased rate of medical comorbidities and unhealthy lifestyle habits even if they do not have a psychiatric diagnosis, shows a worldwide study.

17 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

Researchers recently launched Collaborative Hepatitis Network in Africa

Although it does not receive as much attention as AIDS, hepatitis has long been one of Africa's most serious health problems.

9 Oct 2013

Researchers to develop effective mucosal vaccines based on cell-targeted nanoparticles

The Knut and Alice Wallenberg Foundation will give a little over SEK 16 million to the development of new, highly-efficient mucosal vaccines. The vaccines will be drinkable or given as a nasal spray. Professor Nils Lycke at MIVAC at the Sahlgrenska Academy will in cooperation with researchers at Chalmers University of Technology and Lund University, combine technologies to develop the next generation of effective mucosal vaccines based on immunomodulation and cell-targeted nanoparticles.

9 Oct 2013

Newly discovered compound could be developed as antifungal drug to treat fungal infections

On a molecular level, you have more in common with shower curtain mold or the mushrooms on your pizza than you might think. Humans and fungi share similar proteins, a biological bond that makes curing fungal infections difficult and expensive.

7 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

Tuberculosis News and Research

Latest Tuberculosis News and Research

TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

Reduce tobacco consumption, reduce childhood asthma

Study looks at the feasibility of Xpert test for TB in real-life clinical setting in southern Africa

Researchers complete first phase of landmark study on fungal complications of TB

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Study finds persistent deficiency in new therapeutics for neglected diseases

Researchers identify potential way to combat TB

Tissue-engineered transplants safe and effective in the long term: Study

APPG-GTB members express concern on the growing threat of multi-drug resistant TB

WHO report underlines need for quantum leap in TB care and control

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Psychotic symptoms alone denote medical health risk

Imaxio Sells Genomics Division To Hybrigenics

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Researchers recently launched Collaborative Hepatitis Network in Africa

Researchers to develop effective mucosal vaccines based on cell-targeted nanoparticles

Newly discovered compound could be developed as antifungal drug to treat fungal infections

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Tuberculosis News and Research

Latest Tuberculosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in